NCT07299331 2025-12-23Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone LymphomaZhengzhou UniversityPhase NA Not yet recruiting50 enrolled
NCT06793189 2025-01-27MZL-IPI Risk-adapted Targeted Therapy in Untreated MZLRuijin HospitalPhase 2 Not yet recruiting145 enrolled